vs

Side-by-side financial comparison of ITT INC. (ITT) and Revvity (RVTY). Click either name above to swap in a different company.

ITT INC. is the larger business by last-quarter revenue ($1.1B vs $772.1M, roughly 1.4× Revvity). Revvity runs the higher net margin — 12.7% vs 12.5%, a 0.2% gap on every dollar of revenue. On growth, ITT INC. posted the faster year-over-year revenue change (13.5% vs 5.9%). ITT INC. produced more free cash flow last quarter ($187.4M vs $161.8M). Over the past eight quarters, Revvity's revenue compounded faster (9.0% CAGR vs 7.6%).

ITT Inc., formerly ITT Corporation, is an American manufacturing company based in Stamford, Connecticut. The company produces specialty components for the aerospace, transportation, energy, and industrial markets. ITT's three business units are Industrial Process, Motion Technologies, and Connect and Control Technologies.

Revvity, Inc. is an American company in the life sciences and diagnostics business that is focused on selling to the pharmaceutical and biotechnology industries, especially in relation to approaches making use of new cell therapy or gene therapy developments. Its origins lie with the long-existing company PerkinElmer, which has been in a variety of business lines.

ITT vs RVTY — Head-to-Head

Bigger by revenue
ITT
ITT
1.4× larger
ITT
$1.1B
$772.1M
RVTY
Growing faster (revenue YoY)
ITT
ITT
+7.6% gap
ITT
13.5%
5.9%
RVTY
Higher net margin
RVTY
RVTY
0.2% more per $
RVTY
12.7%
12.5%
ITT
More free cash flow
ITT
ITT
$25.6M more FCF
ITT
$187.4M
$161.8M
RVTY
Faster 2-yr revenue CAGR
RVTY
RVTY
Annualised
RVTY
9.0%
7.6%
ITT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ITT
ITT
RVTY
RVTY
Revenue
$1.1B
$772.1M
Net Profit
$131.7M
$98.4M
Gross Margin
35.5%
Operating Margin
17.0%
14.5%
Net Margin
12.5%
12.7%
Revenue YoY
13.5%
5.9%
Net Profit YoY
3.7%
3.9%
EPS (diluted)
$1.64
$0.86

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ITT
ITT
RVTY
RVTY
Q4 25
$1.1B
$772.1M
Q3 25
$999.1M
$698.9M
Q2 25
$972.4M
$720.3M
Q1 25
$913.0M
$664.8M
Q4 24
$929.0M
$729.4M
Q3 24
$885.2M
$684.0M
Q2 24
$905.9M
$691.7M
Q1 24
$910.6M
$649.9M
Net Profit
ITT
ITT
RVTY
RVTY
Q4 25
$131.7M
$98.4M
Q3 25
$126.9M
$46.7M
Q2 25
$121.0M
$53.9M
Q1 25
$108.4M
$42.2M
Q4 24
$127.0M
$94.6M
Q3 24
$161.1M
$94.4M
Q2 24
$119.2M
$55.4M
Q1 24
$111.0M
$26.0M
Gross Margin
ITT
ITT
RVTY
RVTY
Q4 25
35.5%
Q3 25
35.6%
53.6%
Q2 25
35.7%
54.5%
Q1 25
34.6%
56.5%
Q4 24
34.1%
Q3 24
35.5%
56.3%
Q2 24
34.9%
55.7%
Q1 24
33.0%
54.6%
Operating Margin
ITT
ITT
RVTY
RVTY
Q4 25
17.0%
14.5%
Q3 25
18.0%
11.7%
Q2 25
18.0%
12.6%
Q1 25
16.5%
10.9%
Q4 24
17.2%
16.3%
Q3 24
23.5%
14.3%
Q2 24
17.6%
12.4%
Q1 24
16.4%
6.8%
Net Margin
ITT
ITT
RVTY
RVTY
Q4 25
12.5%
12.7%
Q3 25
12.7%
6.7%
Q2 25
12.4%
7.5%
Q1 25
11.9%
6.4%
Q4 24
13.7%
13.0%
Q3 24
18.2%
13.8%
Q2 24
13.2%
8.0%
Q1 24
12.2%
4.0%
EPS (diluted)
ITT
ITT
RVTY
RVTY
Q4 25
$1.64
$0.86
Q3 25
$1.62
$0.40
Q2 25
$1.52
$0.46
Q1 25
$1.33
$0.35
Q4 24
$1.54
$0.77
Q3 24
$1.96
$0.77
Q2 24
$1.45
$0.45
Q1 24
$1.35
$0.21

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ITT
ITT
RVTY
RVTY
Cash + ST InvestmentsLiquidity on hand
$1.7B
$919.9M
Total DebtLower is stronger
$521.5M
Stockholders' EquityBook value
$4.1B
$7.3B
Total Assets
$6.3B
$12.2B
Debt / EquityLower = less leverage
0.13×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ITT
ITT
RVTY
RVTY
Q4 25
$1.7B
$919.9M
Q3 25
$516.4M
$931.4M
Q2 25
$467.9M
$991.8M
Q1 25
$439.8M
$1.1B
Q4 24
$439.3M
$1.2B
Q3 24
$460.9M
$1.2B
Q2 24
$425.5M
$2.0B
Q1 24
$423.0M
$1.7B
Total Debt
ITT
ITT
RVTY
RVTY
Q4 25
$521.5M
Q3 25
$577.7M
Q2 25
$622.5M
Q1 25
$4.5M
Q4 24
$232.6M
Q3 24
$467.8M
Q2 24
$190.0M
Q1 24
$230.5M
Stockholders' Equity
ITT
ITT
RVTY
RVTY
Q4 25
$4.1B
$7.3B
Q3 25
$2.7B
$7.4B
Q2 25
$2.6B
$7.6B
Q1 25
$2.8B
$7.6B
Q4 24
$2.8B
$7.7B
Q3 24
$2.7B
$7.9B
Q2 24
$2.6B
$7.9B
Q1 24
$2.6B
$7.8B
Total Assets
ITT
ITT
RVTY
RVTY
Q4 25
$6.3B
$12.2B
Q3 25
$5.1B
$12.1B
Q2 25
$5.0B
$12.4B
Q1 25
$4.8B
$12.4B
Q4 24
$4.7B
$12.4B
Q3 24
$4.9B
$12.8B
Q2 24
$4.4B
$13.4B
Q1 24
$4.4B
$13.4B
Debt / Equity
ITT
ITT
RVTY
RVTY
Q4 25
0.13×
Q3 25
0.22×
Q2 25
0.24×
Q1 25
0.00×
Q4 24
0.08×
Q3 24
0.17×
Q2 24
0.07×
Q1 24
0.09×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ITT
ITT
RVTY
RVTY
Operating Cash FlowLast quarter
$227.8M
$182.0M
Free Cash FlowOCF − Capex
$187.4M
$161.8M
FCF MarginFCF / Revenue
17.8%
21.0%
Capex IntensityCapex / Revenue
3.8%
2.6%
Cash ConversionOCF / Net Profit
1.73×
1.85×
TTM Free Cash FlowTrailing 4 quarters
$547.5M
$509.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ITT
ITT
RVTY
RVTY
Q4 25
$227.8M
$182.0M
Q3 25
$173.9M
$138.5M
Q2 25
$153.7M
$134.3M
Q1 25
$113.4M
$128.2M
Q4 24
$223.2M
$174.2M
Q3 24
$123.9M
$147.9M
Q2 24
$157.7M
$158.6M
Q1 24
$57.8M
$147.6M
Free Cash Flow
ITT
ITT
RVTY
RVTY
Q4 25
$187.4M
$161.8M
Q3 25
$146.2M
$120.0M
Q2 25
$137.3M
$115.5M
Q1 25
$76.6M
$112.2M
Q4 24
$186.8M
$149.8M
Q3 24
$87.3M
$125.6M
Q2 24
$134.5M
$136.6M
Q1 24
$30.1M
$129.7M
FCF Margin
ITT
ITT
RVTY
RVTY
Q4 25
17.8%
21.0%
Q3 25
14.6%
17.2%
Q2 25
14.1%
16.0%
Q1 25
8.4%
16.9%
Q4 24
20.1%
20.5%
Q3 24
9.9%
18.4%
Q2 24
14.8%
19.7%
Q1 24
3.3%
20.0%
Capex Intensity
ITT
ITT
RVTY
RVTY
Q4 25
3.8%
2.6%
Q3 25
2.8%
2.6%
Q2 25
1.7%
2.6%
Q1 25
4.0%
2.4%
Q4 24
3.9%
3.4%
Q3 24
4.1%
3.3%
Q2 24
2.6%
3.2%
Q1 24
3.0%
2.7%
Cash Conversion
ITT
ITT
RVTY
RVTY
Q4 25
1.73×
1.85×
Q3 25
1.37×
2.97×
Q2 25
1.27×
2.49×
Q1 25
1.05×
3.03×
Q4 24
1.76×
1.84×
Q3 24
0.77×
1.57×
Q2 24
1.32×
2.87×
Q1 24
0.52×
5.67×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ITT
ITT

Industrial Process$423.1M40%
Motion Technologies$360.8M34%
Connect Control Technologies$271.2M26%

RVTY
RVTY

Immunodiagnostics$240.8M31%
Life Sciences$191.4M25%
Reproductive Health$149.3M19%
Segment Operating Income$132.0M17%
Software$62.3M8%

Related Comparisons